Translational cancer genomics and proteomics
- document 1 document 2 document 3
- niveau 1 niveau 2 niveau 3
- audio 1 audio 2 audio 3
Descriptif
Translational science : how to move from biology to clinical applications
Evaluation of cell-free DNA (cfDNA) is a very attractive tool to serve as “liquid biopsy” to define and establish mutational changes in circulating tumor DNA (ctDNA) during cancer therapy.To identify tumor specific mutations in serum ctDNA associated with resistance against tamoxifen in metastatic breast cancer.Ten ER-positive metastatic breast cancer patients treated with first-line tamoxifen with blood sera available at start therapy (S1), during treatment (S2) and at disease progression (S3) were selected. DNA from normal and primary tumor tissue and cfDNA from sera were sequenced using the Ion Torrent Personal Genome Machine (Ion-PGM). In total 1,242 exons of 45 genes were sequenced up to 5,000 reads depth coverage and single nucleotide variants (SNVs) with at least 2% frequency were defined. Identified SNVs were re-sequenced for confirmation or checked by snapshot assays.The initial analyses revealed 246 SNVs in at least one serum sample, including 96 variants observed at disease progression in serum S3. The 96 variants contained 11 SNVs that were also present within the primary tumor in 6 patients. Re-sequencing at deeper level confirmed all 11 tumor SNVs. These variants occurred in 9 genes and were predicted pathogenic for CDH1, CREBBP, NF1, PIK3CA, SMAD4, and TP53. The variants for CDH1, CREBBP, and SMAD4 were not previously considered tumor-specific in publically available repositories. The remaining 85 variants at disease progression were only observed in serum, and covered 45 serum SNVs merely detected in serum S3 of above 6 patients. Of the 45 SNVs, 3 were already reported in cancer for BRCA1, MAP3K1 and PTCH1, with the first two SNVs considered pathogenic. Moreover, only one not yet reported SNV for AKAP9 (H562Q) was detected in all three sera but not in the tumor within one patient. Re-sequencing of these 4 serum SNVs confirmed only the AKAP9 variant, which is not known yet to be involved in tumor biology.Twelve variants occurring in 10 genes were identified and confirmed after re-sequencing in primary tumor DNA and serum taken at progression, which may be associated with tamoxifen therapy resistance and/or reflecting tumor load. Four of these SNVs have not been linked to to cancer before. Further studies are needed to explore the clinical relevance of the variants as tumor marker or a marker explaining tamoxifen resistance.
Cette présentation a été donnée dans le cadre du ScientificBRIO Day 2 organisé annuellement par le SIRIC BRIO et qui a pour but de réunirtous les acteurs du SIRIC BRIO et plus largement de la cancérologie à Bordeaux.
Thèmes
Notice
Dans la même collection
-
BRIO support to scientistsDessisDamien
BRIO management team was voluntarily built upon various competencies from different horizons (industry, charity…) to provide a broad skillset which aims at supporting the Bordeaux cancer research
-
Bordeaux Cancer InitiativeDessisDamienElustondoFrédéric
Translational science : how to move from biology to clinical applications Upon request of the University, the SIRIC was mandated to develop a transversal cancer axis at the University. The axis
-
A new preclinical model to test the response of breast cancer to genomically targeted therapyIggoRichard
Translational science : how to move from biology to clinical applications The rapid progress in next generation DNA sequencing technology (NGS) means it is now possible, in principle, to obtain a
-
-
-
Standardizing G8 evaluationSoubeyranPierre
Non-pharmaceutical innovations and public health Management of the frail elderly with cancer is a challenge. Beside a poor outcome as compared to younger subjects, physicians will face increased
-
-
Cost-effectiveness analysis for decision making, illustrated theoryBénardAntoine
Interface technology/clinical/SHS/public health : case study interventional radiology In a health care system with limited resources, each euro invested in a health care intervention is no longer
-
Sociology contribution to understanding the (no)diffusion of a medical innovationGorryPhilippe
Interface technology/clinical/SHS/public health : case study interventional radiology We will present results of an undergoing study on the socioeconomic processes of recognition in oncology of a
-
Technique, research and benefitsGrenierNicolasPalussièreJean
Interface technology/clinical/SHS/public health : case study interventional radiology >> Jean Palussière Radiology in oncology or so called interventional oncology is now considered by certain
Sur le même thème
-
JPS 2017 / Dépistage en médecine générale
Journées des Professionnels de Santé 2017 Formation Médicale Continue des Médecins Généralistes >> Yves-Marie Vincent : Dépistage du cancer du sein >> Emmanuel Prothon et
-
A combined laser microdissection and mass spectrometry method for proteomic analysis of tissue sect…RaymondAnne-Aurélie
Clinical and biological samples : opportunities and challenges for translational research A challenge in oncology is to better define the tumor of the patient to study the pathology and of course
-
-
From the OR to clinical database... what for ? The example of UroCCRBernhardJean-Christophe
Clinical and biological samples : opportunities and challenges for translational research The UroCCR database was created to respond to the need on centralization and sharing of the multiple
-
Modelling prognostic capabilities of tumor size : application to colorectal cancerRondeauVirginie
Epidemiology and public health In oncology, the international WHO and RECIST criteria have allowed the standardization of tumor response evaluation in order to identify the time of disease
-
Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomasLe Guyader-PeyrouSandra
Epidemiology and public health The principal aim of this thesis will describe the care pathway of diffuse large B cell lymphoma (DBCL) and follicular lymphoma (FL) in the general population and
-
How studying hematological malignancies subtypes may inform epidemiologic and clinical researchMonnereauAlain
Epidemiology and public health The aim of the talk entitled "How studying hematological malignancies (HM) subtypes may inform epidemiologic and clinical research" is to bring to the audience
-
A new weapon against the tobacco industry : class action lawsuit using a novel epidemiologic param…SiemiatyckiJack
Epidemiology and public health Lawsuits against the tobacco industry, if successful, have the potential to compensate victims of smoking and to diminish the capacity of the tobacco industry to
-
Flash talk - Call for proposal FAC 2014ElustondoFrédéricWodrichHaraldFaustinBenjaminSaltelFrédéricCognetLaurent
Personalized breast cancer therapy based on viral functional assays to score pathway activity Harald Wodrich, University of Bordeaux State-of-the-art mass sequencing technology has paved the road
-
BRIO supporting action to integrated cancer research in BordeauxMeoniPaolo
About BRIO Siric challenges and actions The success of BRIO’s approach and the realization of its potential impact on the translational research community in Bordeaux rely both on the efficient
-
Sarcoma Database: a unique tool for research on mesenchymal tumorsCoindreJean-Michel
Clinical biology session The main sarcoma databases are the Conticabase (https://conticabase.sarcomabcb.org) and the ConticaGist (https://conticagist.sarcomabcb.org) with 18000 patients and which
-
BRIO strategic challenges and the implementation of a translational culture in BordeauxSoubeyranPierre
About BRIO Siric challenges and actions BRIO’s strategic objective is to strengthen Bordeaux’s leadership in Cancer Research through the creation of a dynamic cancer research community, the